Chitosan-adjuvanted Mycoplasma gallisepticum bacterin via intraocular administration enhances Mycoplasma gallisepticum protection in commercial layers.
Poult Sci
; 97(6): 1934-1940, 2018 Jun 01.
Article
em En
| MEDLINE
| ID: mdl-29462425
ABSTRACT
Mycoplasma gallisepticum (MG) causes respiratory signs and economic losses in the poultry industry. MG vaccination is one of the effective prevention and control measures that have been used around the world. Our previous study demonstrated that chitosan-adjuvanted MG bacterin could effectively reduce pathological lesions induced by MG and that chitosan could be used as an adjuvant in MG bacterin. The present study determining the efficacy of MG bacterins against the Thai MG strain was based on vaccine programs. Seven groups (25 layers/group) were received MG bacterins containing 0.5% chitosan or a commercial bacterin via intramuscular (IM) or intraocular (IO) route at 6 and 10 wk of age. Sham-negative and sham-positive controls were groups 1 and 2, respectively. Group 3 IM route of chitosan bacterin followed by IM route of chitosan bacterin; group 4 commercial bacterin via IM route followed by chitosan bacterin via IO route; group 5 commercial bacterin via IM route followed by commercial bacterin via IM route; group 6 chitosan bacterin via IM followed by chitosan bacterin via IO route; and group 7 chitosan bacterin via IO route followed by chitosan bacterin via IO route were determined. At 16 wk of age, all groups, excluding group 1, were challenged intratracheally with 0.1 mL containing Thai MG strain 107 colony-forming unit. At 17, 18, and 20 wk of age, 5 birds in each group were bled for serological testing and swabbed at the choanal cleft for the quantitative real-time PCR assay, the euthanized and necropsied. The results showed that birds vaccinated with a commercial intramuscular bacterin followed by an intraocularly chitosan adjuvant bacterin showed the best protection against the MG challenge. The study indicated that chitosan could be the effective mucosal adjuvant and increased the effectiveness of MG bacterin.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
Base de dados:
MEDLINE
Assunto principal:
Doenças das Aves Domésticas
/
Vacinas Bacterianas
/
Adjuvantes Imunológicos
/
Mycoplasma gallisepticum
/
Quitosana
/
Infecções por Mycoplasma
Limite:
Animals
Idioma:
En
Revista:
Poult Sci
Ano de publicação:
2018
Tipo de documento:
Article